# CASE REPORT ON BRONCHOPNEUMONIA

# DR RAKSHA B H<sup>1</sup>

## <sup>1</sup> INTERN, PHARM D, KRUPANIDHI COLLEGE OF PHARMACY, KARNATAKA, INDIA

## ABSTRACT

Bronchopneumonia, a common type of pneumonia, is characterized by inflammation of the lung's bronchi and surrounding alveoli. It is often caused by bacterial infections, although viral and fungal pathogens can also be involved. This condition primarily affects children, the elderly, and individuals with weakened immune systems. Symptoms include cough, fever, shortness of breath, and chest pain. Diagnosis is typically made through clinical evaluation, chest X-rays, and microbiological tests, including sputum cultures. Treatment includes antibiotic therapy tailored to the causative agent, alongside supportive care such as oxygen therapy and hydration. Early diagnosis and prompt treatment are crucial to prevent complications such as respiratory failure, sepsis, and multiorgan involvement. In this case report, we present a detailed analysis of a patient diagnosed with bronchopneumonia, focusing on the clinical presentation, diagnostic methods, and outcomes of treatment. This case underscores the importance of recognizing bronchopneumonia in its early stages and providing timely intervention to improve patient outcomes.

Key word: - Bronchopneumonia, Risk-factors, Management

### 1. INTRODUCTION: -

Bronchopneumonia is a common form of pneumonia that involves inflammation of the bronchi and the surrounding alveoli in the lungs. It is most often caused by bacterial pathogens such as *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Staphylococcus aureus*, though viral and fungal infections can also contribute. Bronchopneumonia commonly affects vulnerable populations, including young children, elderly individuals, and those with pre-existing conditions like chronic obstructive pulmonary disease (COPD), asthma, or weakened immune systems.

The clinical symptoms of bronchopneumonia typically include fever, cough, shortness of breath, chest pain, and fatigue, which may overlap with other respiratory illnesses, making diagnosis challenging. Radiological imaging, such as chest X-rays, often reveals patchy infiltrates, which are characteristic of bronchopneumonia. Diagnosis is further supported by microbiological tests to identify the causative pathogen.

Treatment primarily involves antibiotic therapy, with the choice of drug tailored to the likely pathogens, along with supportive care such as oxygen therapy and hydration. Timely intervention is crucial, as the disease can rapidly progress, leading to complications like respiratory failure, sepsis, or multi-organ dysfunction, particularly in high-risk patients. This case report aims to highlight the diagnostic approach, treatment strategies, and the clinical outcome of a patient with bronchopneumonia, emphasizing the importance of early detection and intervention in improving patient prognosis.

## CASE REPORT

A 7 months-old child presented with complaints of fever since 4 days ,chest indrawing since 1 day, noisy breathing since 1 day(morning) and tightness od abdomen since 1 day History of present illness involves immunized up to 3 and half months of age in government hospital .Patient was diagnosed as BRONCHOPNEUMONIA AND URINARY TRACT INFECTION. The patient was on medication Syp PCT, Syp Augmentin and Syp Amikacin

Temperature	103.2 °F	
Blood pressure	70/65 mmhg	
Spo2	97% @RA	
Pulse rate	106 bpm	
RR	56/min	

# Table No. 1: Vitals on examination

# Table No. 2: Treatment provided during therapy:

Drug prescribed	Dose	Frequency	Route of administratio
		1.0.1	n IV
Inj. Ceftriaxone	300mg	1-0-1	IV
	8		
Inj.Amikacin	100mg	1-00	IV
	Toomg		
SUP PCT		SOS	RECTAL
NEB 3% NACL		Q6H	NASAL
THE STOTICE		2011	
NEB Adrenalin		1-1-1	NASAL
NEB Adrenann	1ml	1-1-1	NASAL
INJ Piptaz	650mg	1-1-1	IV
	osonig		
SYP OSELTAMIVIR	175.1	1-0-0	PO
	1.75ml		
NEB Salbutamol		Q4H	NASAL
TIED Subdulinor	2ml	<	
SYP Sinarest		1-1-1	PO
STP Sinarest	0.4ml	1-1-1	PO
INJ VIT K	1.8ml	1-0-0	IV
	1.0111		
Zinc Supplement	11	1-0-0	PO
	1ml		
SYP Azithromycin		1-0-1	PO
2 1 1 1 min only only	4ml		
Syp B complex		1-0-1	PO
Syp B complex	1ml	1-0-1	FO
		101	
INJ Dexamethasone	0.2ml	1-0-1	PO
	0.2		
Tonderferon Drops	1.5ml	1-0-0	PO
	1.5111		
Oxygen Support	<b>a</b> 11		
- 76 - Fr	2 liters		
NEB Budesonide		1-0-1	NASAL
TED Dudesonide		1 0 1	INASAL

#### DISCUSSION

- Etiology: Bronchopneumonia is most commonly caused by bacterial infections, though viral and fungal pathogens can also contribute. Bacterial agents, such as *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Staphylococcus aureus* (including MRSA), and *Klebsiella pneumoniae*, are frequently responsible for both community-acquired and hospital-acquired infections. Viral causes, including *Influenza viruses*, *Respiratory Syncytial Virus (RSV)*, and *Adenovirus*, are particularly common in children, the elderly, and those with compromised immune systems. Fungal infections, though rare, can occur in immunocompromised individuals and are typically caused by organisms like *Aspergillus* and *Histoplasma*. Additionally, aspiration pneumonia, where food or liquids are inhaled into the lungs, can also lead to bronchopneumonia, especially in individuals with swallowing difficulties or neurological conditions. The wide range of potential pathogens underscores the importance of accurate diagnosis to guide effective treatment.
- > Clinical Presentation: Symptoms of BRONCOPNEMONIA come on suddenly may include-
- I. Sudden fever: A high fever that can spike quickly.
- II. Rapid onset of cough: A productive cough that may start suddenly, often accompanied by yellow or green sputum.
- III. Shortness of breath: Difficulty breathing, which can occur quickly, especially with physical activity.
- IV. Chest pain: Sharp or pleuritic chest pain that intensifies with deep breaths or coughing.
- V. Fatigue and weakness: Sudden onset of tiredness that worsens with activity.
- VI. Tachypnea: Increased respiratory rate that develops rapidly.
- VII. Wheezing and crackles: Sudden abnormal lung sounds due to inflammation and airway obstruction
  - Diagnosis: The diagnosis of bronchopneumonia involves a combination of clinical assessment and diagnostic tests. A physical examination reveals symptoms like fever, cough, and abnormal lung sounds. Chest X-rays are essential to identify patchy infiltrates characteristic of the condition. Blood tests, including a complete blood count and blood cultures, help detect infection and identify the causative pathogen. Sputum cultures or PCR testing further aid in identifying the specific organism. In some cases, pulse oximetry or arterial blood gas (ABG) tests are used to assess oxygen levels. A CT scan may be employed for more detailed imaging in severe cases. Early diagnosis is critical for effective treatment.
  - > **Treatment**:Treatment for bronchopneumonia typically involves antibiotics for bacterial infections and antivirals for viral causes, alongside supportive care. In severe cases, hospitalization may be required for intravenous antibiotics, oxygen therapy, and fluid management. Pain relief and fever management are important, and corticosteroids may be used in some cases to reduce inflammation. Early and appropriate treatment is vital to prevent complications like respiratory failure or sepsis.
  - Complications: Without prompt treatment, bronchopneumonia can lead to serious complications such as respiratory failure, sepsis, lung abscesses, pleural effusion, and acute respiratory distress syndrome (ARDS). In high-risk individuals, it can progress to multi-organ dysfunction. Early intervention is crucial to prevent these complications.

#### **Conclusion :-**

Bronchopneumonia is a potentially serious condition that requires early diagnosis and treatment to prevent complications such as respiratory failure and sepsis. Timely antibiotic therapy, supportive care, and appropriate diagnostic measures are crucial for effective management. Early intervention significantly improves patient outcomes, especially in high-risk groups.

Acknowledgment: - I would like to thank the organization for all the support

#### REFFERENCES

- .Cizman M. The use and resistance to antibiotics in the community. Int J Antimicrob Agents. 2003;21(4):297–307. doi: 10.1016/s0924-8579(02)00394-1. [DOI] [PubMed] [Google Scholar]
- Agweyu A, Kibore M, Digolo L, Kosgei C, Maina V, Mugane S, Muma S, Wachira J, Waiyego M, Maleche-Obimbo E. Prevalence and correlates of treatment failure among Kenyan children hospitalised with severe community-acquired pneumonia:a prospective study of the clinical effectiveness of WHO pneumonia case management guidelines. Trop Med Int Health. 2014;19(11):1310–20. doi: 10.1111/tmi.12368. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, Kaplan SL, Mace SE, McCracken GH, Jr, Moore MR, St Peter SD, Stockwell JA, Swanson JT. Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Executive summary:the management of community-acquired pneumonia in infants and children older than 3 months of age:clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53(7):617–30. doi: 10.1093/cid/cir625. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kabra SK, Lodha R, Pandey RM. Antibiotics for community-acquired pneumonia in children. Cochrane Database Syst Rev. 2010;3:CD004874. doi: 10.1002/14651858.CD004874.pub2. Update in:Cochrane Database Syst Rev. 2013; 6:CD004874. [DOI] [PubMed] [Google Scholar]
- Harris JA. Antimicrobial therapy of pneumonia in infants and children. Semin Respir Infect. 1996;11(3):139–47. [PubMed] [Google Scholar]
- Lodha R, Kabra SK, Pandey RM. Antibiotics for community-acquired pneumonia in children. Cochrane Database Syst Rev. 2013;6:CD004874. doi: 10.1002/14651858.CD004874.pub4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Toska A, Geitona M. Antibiotic resistance and irrational prescribing in paediatric clinics in Greece. Br J Nurs. 2015;24(1):28–33. doi: 10.12968/bjon.2015.24.1.28. [DOI] [PubMed] [Google Scholar]
- Leekha S, Terrell CL, Edson RS. General principles of antimicrobial therapy. Mayo Clin Proc. 2011;86(2):156–67. doi: 10.4065/mcp.2010.0639. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rooshenas L, Wood F, Brookes-Howell L, Evans MR, Butler CC. The influence of children's day care on antibiotic seeking:a mixed methods study. Br J Gen Pract. 2014;64(622):e302–12. doi: 10.3399/bjgp14X679741. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Muszynski JA, Knatz NL, Sargel CL, Fernandez SA, Marquardt DJ, Hall MW. Timing of correct parenteral antibiotic initiation and outcomes from severe bacterial community-acquired pneumonia in children. Pediatr Infect Dis J. 2011;30(4):295–301. doi: 10.1097/INF.0b013e3181ff64ec. [DOI] [PubMed] [Google Scholar]